Form 8-K - Current report:
SEC Accession No. 0001213900-25-032135
Filing Date
2025-04-15
Accepted
2025-04-15 16:30:25
Documents
15
Period of Report
2025-04-15
Items
Item 2.02: Results of Operations and Financial Condition
Item 4.02: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0238372-8k_abvcbio.htm   iXBRL 8-K 30163
2 PRESS RELEASE ea023837201ex99-1_abvcbio.htm EX-99.1 20978
3 GRAPHIC ex99-1_001.jpg GRAPHIC 2336
  Complete submission text file 0001213900-25-032135.txt   233513

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE abvc-20250415.xsd EX-101.SCH 3020
5 XBRL PRESENTATION FILE abvc-20250415_pre.xml EX-101.PRE 22362
6 XBRL LABEL FILE abvc-20250415_lab.xml EX-101.LAB 34239
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0238372-8k_abvcbio_htm.xml XML 3570
Mailing Address 44370 OLD WARM SPRINGS BLVD. FREMONT CA 94538
Business Address 44370 OLD WARM SPRINGS BLVD. FREMONT CA 94538 510-668-0881
ABVC BIOPHARMA, INC. (Filer) CIK: 0001173313 (see all company filings)

EIN.: 260014658 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40700 | Film No.: 25839947
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)